Tompkins Financial Corp lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 22.4% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 121 shares of the company’s stock after selling 35 shares during the quarter. Tompkins Financial Corp’s holdings in IDEXX Laboratories were worth $40,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in IDXX. Alliancebernstein L.P. increased its holdings in shares of IDEXX Laboratories by 740.5% in the 1st quarter. Alliancebernstein L.P. now owns 1,264,276 shares of the company’s stock valued at $306,258,000 after acquiring an additional 1,113,849 shares during the period. BlackRock Inc. raised its holdings in shares of IDEXX Laboratories by 6.0% in the first quarter. BlackRock Inc. now owns 7,868,095 shares of the company’s stock worth $1,905,968,000 after acquiring an additional 443,250 shares during the last quarter. Wellington Management Group LLP boosted its position in IDEXX Laboratories by 5,034.2% during the first quarter. Wellington Management Group LLP now owns 415,410 shares of the company’s stock worth $100,629,000 after acquiring an additional 407,319 shares during the last quarter. WCM Investment Management LLC purchased a new position in IDEXX Laboratories during the first quarter worth about $70,465,000. Finally, Congress Asset Management Co. MA increased its position in IDEXX Laboratories by 19,761.6% during the first quarter. Congress Asset Management Co. MA now owns 222,053 shares of the company’s stock worth $53,790,000 after purchasing an additional 220,935 shares during the last quarter. Institutional investors and hedge funds own 88.58% of the company’s stock.

In other IDEXX Laboratories news, VP Giovani Twigge sold 14,070 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $307.73, for a total transaction of $4,329,761.10. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jonathan W. Ayers sold 21,130 shares of the business’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $291.63, for a total transaction of $6,162,141.90. Following the sale, the director now directly owns 831,597 shares in the company, valued at $242,518,633.11. The disclosure for this sale can be found here. Insiders have sold 106,182 shares of company stock valued at $31,409,008 over the last ninety days. Insiders own 2.53% of the company’s stock.

Shares of NASDAQ:IDXX opened at $397.75 on Friday. The company has a market capitalization of $33.78 billion, a PE ratio of 79.55, a price-to-earnings-growth ratio of 5.75 and a beta of 0.81. The company has a debt-to-equity ratio of 7.06, a quick ratio of 0.60 and a current ratio of 0.85. The stock has a fifty day moving average of $335.38 and a 200-day moving average of $286.60. IDEXX Laboratories, Inc. has a one year low of $168.65 and a one year high of $407.86.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Friday, July 31st. The company reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.17 by $0.55. IDEXX Laboratories had a return on equity of 264.71% and a net margin of 17.78%. The company had revenue of $637.20 million for the quarter, compared to analyst estimates of $589.98 million. During the same period in the previous year, the firm earned $1.43 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 2.8% compared to the same quarter last year. As a group, research analysts forecast that IDEXX Laboratories, Inc. will post 4.98 EPS for the current fiscal year.

A number of equities analysts have weighed in on IDXX shares. TheStreet raised shares of IDEXX Laboratories from a “c+” rating to a “b-” rating in a research report on Thursday, April 30th. Bank of America boosted their price objective on IDEXX Laboratories from $300.00 to $390.00 and gave the company a “buy” rating in a research report on Monday, July 20th. Stifel Nicolaus upped their price target on shares of IDEXX Laboratories from $280.00 to $375.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, BidaskClub cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 6th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $317.14.

About IDEXX Laboratories

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Featured Story: Stock Market – What is a circuit breaker?

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.